---
title: "Continuous glucose monitoring and self-reported behaviour change: perceived mechanisms and app fea"
id: "medrxiv-22-how-continuous-glucose-monitoring-may-support-behaviour-change-perceived"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-how-continuous-glucose-monitoring-may-support-behaviour-change-perceived"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.19.26365948v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Continuous glucose monitoring and self-reported behaviour change: perceived mechanisms and app fea
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-how-continuous-glucose-monitoring-may-support-behaviour-change-perceived
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.19.26365948v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study surveyed 112 U.S. adults with type 1 or type 2 diabetes who had used a **Dexcom** or **Abbott Libre** continuous glucose monitor (CGM) within the prior 12 months. - Participants had a mean age of 54.5 years and 60.7% were female; the study received Georgetown University IRB approval and electronic informed consent was obtained. - Respondents rated 26 mechanism-of-action (MoA) statements mapped to the **COM-B** model (Capability, Opportunity, Motivation-Behaviour) and identified which app features contributed to each MoA. - The cohort endorsed a median of 18 MoAs, with endorsements most frequently falling into knowledge, skills, and behavioural-consequence domains. - Real-time glucose values and graphical displays were commonly attributed to multiple MoAs by users. - Reported behaviour change attributed to CGM was high for diet (82.1%) and moderate for physical activity (46.4%). - Each additional MoA endorsed was associated with greater odds of reported diet change (OR 1.27, 95% CI 1.15–1.44) and physical activity change (OR 1.27, 95% CI 1.16–1.43). - Among COM-B domains, Motivation provided the strongest distinct predictive contribution for self-reported behaviour change. - The authors made their de-identified dataset available via Zenodo; competing interests and funding sources were disclosed in the preprint.
## Clinical Analysis & Structured Key Points
How continuous glucose monitoring may support behaviour change: perceived mechanisms and app feature attribution in a cross-sectional survey | medRxiv Skip to main content How continuous glucose monitoring may support behaviour change: perceived mechanisms and app feature attribution in a cross-sectional survey Michelle R. Jospe , Lauren Connell Bohlen , Jacob Crawshaw , Jessie Somerville , Elizabeth LaRegina , Holly J. Willis , Sally K. Gustafson , Susan M. Schembre doi: https://doi.org/10.64898/2026.10.19.26365948 Michelle R. Jospe 1 Georgetown University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lauren Connell Bohlen 2 Brown University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jacob Crawshaw 3 Ottawa Hospital Research Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jessie Somerville 1 Georgetown University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elizabeth LaRegina 1 Georgetown University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Holly J. Willis 4 HealthPartners Institute Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sally K. Gustafson 4 HealthPartners Institute Find this author on Google Scholar Find this author on PubMed Search for this author on this site Susan M. Schembre 1 Georgetown University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: ss4731{at}georgetown.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Aims: To understand how users believe continuous glucose monitoring (CGM) changes their behaviour, which app features they credit, and whether endorsing more mechanisms of action (MoAs) is linked to reported diet and physical activity change. Methods: We surveyed 112 U.S. adults with type 1 or type 2 diabetes who had used a Dexcom or Abbott Libre CGM within 12 months. Participants rated 26 MoA statements mapped to the Capability, Opportunity, Motivation-Behaviour (COM-B) model, identified contributing app features, and reported CGM-attributed diet and physical activity change. Logistic regression examined MoA count and COM-B domains as predictors of behaviour change. Results: Participants (mean age 54.5 years; 60.7% female) reported dietary (82.1%) and physical activity (46.4%) change and endorsed a median of 18 MoAs, most often relating to knowledge, skills and behavioural consequences. Real-time glucose and graphs were attributed to many MoAs. Each additional MoA was associated with higher odds of dietary (OR 1.27, 95% CI 1.15-1.44) and physical activity change (OR 1.27, 95% CI 1.16-1.43). Motivation made the strongest distinct contribution among COM-B domains. Conclusions: Users perceive CGM as engaging many behavioural mechanisms; endorsing more was linked to behaviour change. Motivation may be a key target for CGM-based behavioural support. Competing Interest Statement MRJ reports former consultation to Zoe and WeightWatchers International, Inc. SMS reports unpaid consultation for Viocare. HJW has received research support, product support for clinical trials, served as a consultant, participated in an educational speaker's bureau, and/or has been on an advisory board for Abbott Diabetes Care and Dexcom. HJW has received no personal income from any of these services, all payments go to the non-profit HealthPartners Institute. SKG reports that HealthPartners Institute has received research funding on her behalf from Dexcom but that she has not received any direct payment or compensation. All other authors declare no competing interests. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the Georgetown University Institutional Review Board (approval number STUDY000010019). All participants provided electronic informed consent before completing the survey. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The de-identified dataset and codebook generated and analysed during the current study are available in the Zenodo repository, 10.5281/zenodo.23090454. https://zenodo.org/records/23090454 Funder Information Declared National Institutes of Health , P30CA051008 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following How continuous glucose monitoring may support behaviour change: perceived mechanisms and app feature attribution in a cross-sectional survey Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share How continuous glucose monitoring may support behaviour change: perceived mechanisms and app feature attribution in a cross-sectional survey Michelle R. Jospe , Lauren Connell Bohlen , Jacob Crawshaw , Jessie Somerville , Elizabeth LaRegina , Holly J. Willis , Sally K. Gustafson , Susan M. Schembre medRxiv 2026.10.19.26365948; doi: https://doi.org/10.64898/2026.10.19.26365948 Share This Article: Copy Citation Tools How continuous glucose monitoring may support behaviour change: perceived mechanisms and app feature attribution in a cross-sectional survey Michelle R. Jospe , Lauren Connell Bohlen , Jacob Crawshaw , Jessie Somerville , Elizabeth LaRegina , Holly J. Willis , Sally K. Gustafson , Susan M. Schembre medRxiv 2026.10.19.26365948; doi: https://doi.org/10.64898/2026.10.19.26365948 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (632) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4939) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (670) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1665) Epidemiology (16149) Forensic Medicine (35) Gastroenterology (1234) Genetic and Genomic Medicine (7200) Geriatric Medicine (747) Health Economics (1088) Health Informatics (5213) Health Policy (1454) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16420) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (738) Neurology (7482) Nursing (375) Nutrition (1112) Obstetrics and Gynecology (1277) Occupational and Environmental Health (1028) Oncology (3707) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (491) Palliative Medicine (142) Pathology (716) Pediatrics (1842) Pharmacology and Therapeutics (747) Primary Care Research (780) Psychiatry and Clinical Psychology (6059) Public and Global Health (9907) Radiology and Imaging (2497) Rehabilitation Medicine and Physical Therapy (1498) Respiratory Medicine (1263) Rheumatology (655) Sexual and Reproductive Health (793) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [Olive oil before carbs and blood sugar: what the mouse study found](https://medichelpline.com/clinical-feed/medical-news-today-0-olive-oil-shot-trend-what-science-really-says-about-fat-and-glucose-response.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [Diabetic retinopathy regression rates in very mild and mild NPDR in an IHS teleophthalmology cohort](https://medichelpline.com/clinical-feed/plos-one-2-rates-of-nonproliferative-diabetic-retinopathy-npdr-regression-among-patients.md)
- [Paired plasma and urine metabolomics predict incident type 2 diabetes in Japanese cohort](https://medichelpline.com/clinical-feed/medrxiv-13-paired-plasma-and-urine-metabolomics-and-incident-type-2-diabetes-a-population.md)
- [Personalized SGLT2 Inhibitor Policy Learning Using Counterfactual SCM](https://medichelpline.com/clinical-feed/medrxiv-13-counterfactual-policy-learning-for-personalized-treatment-using-sglt2-inhibitors.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.